Pharma CEO Business Operations for Medical Affairs

Medical Affairs as a Strategic Business Function

In the modern pharmaceutical organization, medical affairs has evolved from a compliance-focused support function into a genuinely strategic business operation. The shift reflects changes in the external environment: healthcare payers and integrated delivery networks demand clinical evidence beyond regulatory approval, key opinion leaders expect scientific dialogue rather than promotional messaging, and the boundaries between commercial and medical activities are more tightly regulated than ever.

For pharma CEOs, the strategic question is not whether to invest in medical affairs, but how to build a medical affairs function that creates real competitive advantage through scientific credibility, field excellence, and intelligent evidence generation.

This article provides a framework for CEOs to evaluate, build, and operationalize a high-performance medical affairs organization.

Understanding the Medical Affairs Mandate

Before addressing operational structure and metrics, it is worth being clear about what medical affairs is responsible for in a well-run pharmaceutical organization.

Medical affairs serves as the scientific interface between the company and the external medical community. Its primary stakeholders include key opinion leaders (KOLs) in relevant therapeutic areas, academic medical centers and research institutions, integrated delivery networks, pharmacy benefit managers, and health technology assessment bodies in global markets.

The core activities of medical affairs include medical information provision, medical science liaison (MSL) field engagement, evidence generation through Phase IV studies and real-world evidence programs, publication strategy and scientific communications, health economics and outcomes research (HEOR), medical education support, and advisory board management.

What medical affairs is explicitly not responsible for is promotional activity. The firewall between medical and commercial functions is both a regulatory requirement and an ethical imperative. CEOs who blur this line, even implicitly by measuring medical affairs on commercial metrics, create significant legal and reputational risk.

The Medical Science Liaison as a Field Asset

The MSL organization is the operational centerpiece of most medical affairs functions. MSLs are field-based scientific experts, typically holding advanced degrees (PhDs, PharmDs, or MDs), who engage in peer-level scientific dialogue with key external stakeholders.

Effective MSLs are invaluable: they bring field-level scientific intelligence back into the organization, build genuine relationships with the KOLs who influence prescribing patterns and treatment guidelines, and support investigator-initiated studies and real-world evidence generation. Ineffective MSLs are expensive and potentially problematic, creating compliance risk by straying into promotional territory and wasting KOL time with scientifically thin interactions.

Building a High-Performance MSL Organization

CEOs overseeing medical affairs operations should apply the same talent rigor to the MSL organization that they apply to any other high-impact field force. Key operational levers include:

Hiring standards. MSL hiring should prioritize genuine scientific expertise in the relevant therapeutic area alongside communication and relationship-building skills. The ability to engage in credible peer-level scientific dialogue is not teachable in onboarding training; it must be present at hire.

Territory design and account prioritization. MSL territories should be sized based on the density of high-value KOL relationships and the scientific complexity of the therapeutic area, not on arbitrary geographic divisions. Account prioritization should drive where MSLs invest their time, focusing on the external stakeholders whose scientific engagement creates the most strategic value.

Metrics that reflect scientific value. The metrics commonly used to manage MSL performance, including number of interactions, number of KOLs reached, and interaction duration, measure activity rather than impact. Progressive medical affairs organizations supplement activity metrics with quality measures: KOL satisfaction, depth of scientific dialogue captured in field reports, and conversion of external scientific insights into internal decisions. MSL performance management should reinforce scientific excellence, not transactional volume.

Continuous scientific development. MSLs must stay current with rapidly evolving scientific literature. The organization’s investment in scientific education for MSLs, including attendance at congresses, access to key publications, and regular internal scientific updates, directly affects field performance.

Evidence Generation as a Strategic Function

One of the most strategically important and operationally complex responsibilities of medical affairs is evidence generation. As payers and HTA bodies impose increasingly stringent evidence requirements for formulary access and reimbursement, the evidence package supporting a product launch must go well beyond the pivotal clinical trials required for regulatory approval.

Real-World Evidence Programs

Real-world evidence (RWE) programs use data from clinical practice, registries, and administrative databases to characterize how a product performs outside the controlled conditions of a randomized clinical trial. For CEOs, RWE is increasingly a commercial imperative: payers in the US and globally use RWE to make coverage and reimbursement decisions, and the organizations that have robust RWE programs in place at or before launch have a significant advantage.

Building RWE capability requires investment in several operational areas: data access agreements with healthcare systems and claims databases, analytical infrastructure and data science expertise, relationships with academic research partners, and internal operational processes for designing and executing studies that meet payer-quality evidence standards.

CEOs should ensure that RWE strategy is integrated into the launch planning process from early development stages, not retrofitted after approval as an afterthought.

Health Economics and Outcomes Research

HEOR is the function within medical affairs responsible for demonstrating the economic and patient-centered value of a product to payers, formulary committees, and HTA bodies. As value-based payment models become more prevalent, HEOR expertise is increasingly a prerequisite for commercial success.

An effective HEOR function develops health economic models that quantify product value in terms relevant to payer decision-making, designs and analyzes patient-reported outcomes studies, and produces publications and economic dossiers that support market access.

CEOs should ensure HEOR is resourced adequately and integrated early into both clinical development planning and pre-launch commercial strategy. The organizations that treat HEOR as an afterthought consistently struggle with access and reimbursement at launch.

KOL Engagement Strategy

Key opinion leaders remain among the most influential actors in pharmaceutical markets. Their participation in clinical guidelines development, their roles as educators at medical congresses, and their influence over peer prescribers give them disproportionate impact on how new treatments are adopted.

CEOs should understand the overall KOL strategy for each therapeutic area: who are the most influential scientific leaders, what is the nature of the organization’s current relationship with them, and is the medical affairs engagement plan commensurate with their strategic importance?

Advisory Boards

Advisory boards, when properly constituted and managed, are one of the highest-value tools in the medical affairs toolkit. They bring together groups of external scientific experts to provide input on clinical development strategy, evidence generation priorities, scientific communication plans, and unmet medical needs.

Operationally effective advisory boards have clear objectives for each meeting, pre-read materials that allow participants to engage substantively, and internal processes for capturing and acting on advisor input. The test of a good advisory board is not whether the meeting runs smoothly, but whether the scientific insights generated actually influence internal decisions.

Advisory board management also carries compliance requirements that CEOs should ensure are met consistently: independent fair market value assessments for advisor compensation, complete documentation of meeting content, and clear separation from any commercial activities.

Medical Affairs and Commercial Alignment

The relationship between medical affairs and commercial functions is one of the most organizationally sensitive in the pharmaceutical industry. The two functions must coordinate closely enough to ensure that the evidence base supports commercial strategy and that medical insights from the field inform commercial planning. At the same time, the firewall protecting the scientific independence of medical affairs must be maintained.

CEOs are uniquely positioned to model and reinforce the norms that govern this relationship. When the commercial organization pressures medical affairs to support off-label use, to soften a negative evidence discussion, or to use KOL relationships as de facto sales support, the CEO’s response sets the standard for the entire organization.

The appropriate model is one of aligned strategy but independent execution. Medical and commercial leaders should collaborate on pre-launch evidence planning, understanding unmet needs, and identifying the scientific questions that matter most to payers and prescribers. Medical affairs should then execute its activities according to scientific merit and regulatory standards, without commercial pressure on individual MSL interactions or publication decisions.

According to research from McKinsey, pharmaceutical organizations that achieve strong medical-commercial alignment while maintaining scientific independence consistently outperform peers on market access metrics and product uptake rates.

Building Medical Affairs Operational Infrastructure

Behind the field-facing and scientific activities of medical affairs lies a set of operational functions that determine whether the function can scale and execute effectively.

Medical Information

Medical information provides responses to unsolicited questions from healthcare providers, patients, and payors about company products. This function carries significant compliance requirements: responses must be accurate, non-promotional, and appropriately documented. As digital channels multiply the volume and variety of medical information inquiries, CEOs should ensure the medical information function has the staffing, technology, and process infrastructure to respond consistently and in compliance.

Publication Planning

Scientific publications in peer-reviewed journals and congress presentations are primary vehicles for communicating the evidence base to the medical community. Publication planning is the operational process that ensures key data are communicated effectively, transparently, and in compliance with Good Publication Practice guidelines.

CEOs should be aware that publication strategy carries reputational risk. Organizations that have been criticized for publication bias, ghost-writing, or delayed disclosure of negative data face lasting credibility damage with the scientific community. Rigorous, transparent publication practices are both an ethical requirement and a strategic asset.

Regulatory Considerations for Medical Affairs Activities

Medical affairs activities are subject to FDA regulation under the rules governing scientific exchange, medical education, and publication. CEOs should ensure their chief medical officer and legal/compliance leadership are aligned on the regulatory standards that govern medical affairs activities and that medical affairs staff receive regular training on these standards.

The pharma patient access framework addresses how medical affairs evidence generation connects to the broader patient access and market access strategy.

Metrics for Medical Affairs Performance

Measuring the contribution of medical affairs is an ongoing challenge in the industry. Because medical affairs activities are designed to operate independently of commercial objectives, applying commercial metrics to the function creates both compliance risk and perverse incentives.

A more appropriate measurement framework uses metrics that reflect scientific value and stakeholder engagement quality:

KOL engagement depth (breadth and quality of scientific dialogue with priority thought leaders)
Scientific intelligence capture rate (percentage of MSL interactions generating actionable field insights)
Evidence generation milestones (RWE study completion, HEOR model development, publication outputs)
Medical information response accuracy and timeliness
Advisory board input utilization (percentage of advisor recommendations incorporated into internal decisions)
MSL scientific competency assessments
Compliance audit results (including documentation quality and interaction appropriateness)

These metrics should be reviewed by the Chief Medical Officer and the CEO regularly, with particular attention to any patterns suggesting compliance risk.

The CEO’s Role in Medical Affairs Governance

Medical affairs governance is a CEO responsibility, not only because the function carries compliance risk, but because the scientific integrity of the organization is a CEO-level asset. A pharmaceutical company’s reputation with the medical community, built over years of rigorous evidence generation and transparent communication, can be damaged quickly by perceived scientific compromise.

CEOs should ensure they have direct visibility into the organization’s medical affairs strategy, are personally aware of any significant compliance concerns surfaced through audit or field reports, and are modeling the expectation that scientific integrity is non-negotiable at every level of the organization.

Strong medical affairs operations create long-term competitive advantage that is difficult to replicate: deep relationships with scientific leaders, a credible evidence base, and a reputation for scientific rigor that opens doors across the medical community. For CEOs who want to build pharmaceutical organizations built to last, medical affairs excellence is an essential operational investment.

For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.